Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle

J. Gumulec, J. Balvan, M. Sztalmachova, M. Raudenska, V. Dvorakova, L. Knopfova, H. Polanska, K. Hudcova, B. Ruttkay-Nedecky, P. Babula, V. Adam, R. Kizek, M. Stiborova, M. Masarik,

. 2014 ; 44 (3) : 923-933.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074379

Differences in the antioxidant system, apoptotic mechanism and in cell cycle between prostatic cell lines could partially elucidate the development of cisplatin resistance. The aim of this study was to identify the most characteristic parameter for a particular cell line and/or a particular cisplatin treatment using a general regression model and to assess whether it is possible to use measured parameters as markers of cisplatin resistance. This study integrates the results of viability, antioxidant, flow cytometric and quantitative PCR assays in order to characterize the resistance of prostate cancer to cisplatin. Cell growth using metabolic- (MTT) and impedance-based assays, the expression of key cell death signaling proteins (p53, Bax and Bcl-2), cell cycle, activity of antioxidant system-related proteins (superoxide dismutase, glutathione peroxidase, glutathione reductase and metallothionein) and free radical scavenging capacity assays [free radicals (FR), ferric reducing antioxidant power (FRAP), ABTS] were analyzed in the cell lines 22Rv1, PC-3 and PNT1A with respect to rising concentrations (0-150 µM) and different length of cisplatin treatment (12-72 h). The non-functional-p53 PC-3 cell line showed decreased BAX (p<0.05) and, in contrast to PNT1A and 22Rv1, no cisplatin-induced effects on cell cycle. All cell lines showed increasing levels of free radical scavenging activity by ABTS, FRAP and FR assays in a time- and dose-dependent manner (r>0.76 at p<0.001 for ABTS, FRAP and FR at p<0.001). PC-3 showed increased (p<0.05) levels of free radical scavenging activity by ABTS and FR methods. These findings, together with significantly elevated MT, decreased p53 and Bax indicate PC-3 to be cisplatin-resistant. The differences in the antioxidant system and apoptotic mechanisms in PC-3 cells may elucidate the development of cisplatin resistance and indicate that this cell line may be further studied as a model of cytostatic resistance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074379
003      
CZ-PrNML
005      
20170411121857.0
007      
ta
008      
141006s2014 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ijo.2013.2223 $2 doi
035    __
$a (PubMed)24366574
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Gumulec, Jaromir $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
245    10
$a Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle / $c J. Gumulec, J. Balvan, M. Sztalmachova, M. Raudenska, V. Dvorakova, L. Knopfova, H. Polanska, K. Hudcova, B. Ruttkay-Nedecky, P. Babula, V. Adam, R. Kizek, M. Stiborova, M. Masarik,
520    9_
$a Differences in the antioxidant system, apoptotic mechanism and in cell cycle between prostatic cell lines could partially elucidate the development of cisplatin resistance. The aim of this study was to identify the most characteristic parameter for a particular cell line and/or a particular cisplatin treatment using a general regression model and to assess whether it is possible to use measured parameters as markers of cisplatin resistance. This study integrates the results of viability, antioxidant, flow cytometric and quantitative PCR assays in order to characterize the resistance of prostate cancer to cisplatin. Cell growth using metabolic- (MTT) and impedance-based assays, the expression of key cell death signaling proteins (p53, Bax and Bcl-2), cell cycle, activity of antioxidant system-related proteins (superoxide dismutase, glutathione peroxidase, glutathione reductase and metallothionein) and free radical scavenging capacity assays [free radicals (FR), ferric reducing antioxidant power (FRAP), ABTS] were analyzed in the cell lines 22Rv1, PC-3 and PNT1A with respect to rising concentrations (0-150 µM) and different length of cisplatin treatment (12-72 h). The non-functional-p53 PC-3 cell line showed decreased BAX (p<0.05) and, in contrast to PNT1A and 22Rv1, no cisplatin-induced effects on cell cycle. All cell lines showed increasing levels of free radical scavenging activity by ABTS, FRAP and FR assays in a time- and dose-dependent manner (r>0.76 at p<0.001 for ABTS, FRAP and FR at p<0.001). PC-3 showed increased (p<0.05) levels of free radical scavenging activity by ABTS and FR methods. These findings, together with significantly elevated MT, decreased p53 and Bax indicate PC-3 to be cisplatin-resistant. The differences in the antioxidant system and apoptotic mechanisms in PC-3 cells may elucidate the development of cisplatin resistance and indicate that this cell line may be further studied as a model of cytostatic resistance.
650    _2
$a antioxidancia $x metabolismus $7 D000975
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a buněčný cyklus $x účinky léků $x genetika $7 D002453
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a cisplatina $x terapeutické užití $7 D002945
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory prostaty $x farmakoterapie $x genetika $x patologie $7 D011471
650    _2
$a signální transdukce $x genetika $7 D015398
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Balvan, Jan $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
700    1_
$a Sztalmachova, Marketa $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
700    1_
$a Raudenska, Martina $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
700    1_
$a Dvorakova, Veronika $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
700    1_
$a Knopfová, Lucia $u Department of Experimental Biology, Faculty of Science, Masaryk University, CZ-625 00 Brno, Czech Republic. $7 xx0208986
700    1_
$a Polanska, Hana $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
700    1_
$a Hudcova, Kristyna $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
700    1_
$a Ruttkay-Nedecky, Branislav $u Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-613 00 Brno, Czech Republic.
700    1_
$a Babula, Petr $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, CZ-612 42 Brno, Czech Republic.
700    1_
$a Adam, Vojtěch $u Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-613 00 Brno, Czech Republic. $7 xx0064599
700    1_
$a Kizek, Rene $u Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-613 00 Brno, Czech Republic.
700    1_
$a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, CZ-128 40 Prague 2, Czech Republic.
700    1_
$a Masarik, Michal $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic.
773    0_
$w MED00002350 $t International journal of oncology $x 1791-2423 $g Roč. 44, č. 3 (2014), s. 923-933
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24366574 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20170411122156 $b ABA008
999    __
$a ok $b bmc $g 1042262 $s 873291
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 44 $c 3 $d 923-933 $i 1791-2423 $m International journal of oncology $n Int J Oncol $x MED00002350
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Možnosti archivace